Notice of Intent to Publish a Funding Opportunity Announcement for Cardiovascular Repository – Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed) (NOT-DK-24-001)

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on the cardiovascular complications of type 1 diabetes (T1D) as part of the NIH Cardiovascular Repository for T1D (CaRe-T1D).  Cardiovascular disease (CVD) is the leading cause of death for individuals with T1D and significantly shorten their lives.  CaRe-T1D was initiated with the goal of establishing a biorepository of human CV tissue and a scientific consortium to advance and support discovery and mechanistic research that increase the understanding of CVD in T1D.  The first phase launched the biorepository and now in the second phase investigative teams will be added to form a consortium with the biorepository serving as the Coordinating Center (CC).  The goal of the new initiative is to attract investigative teams with complementary interests and expertise who will leverage these resources through individual and collaborative studies to advance our knowledge of the pathogenesis of CVD in T1D. 

Application due date: April 11, 2024 

Single Source for continuation of the Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed) (RFA-DK-25-002)

This is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement award to the University of Pennsylvania. The purpose of this Single Source is to extend the Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D). The HPAP-T2D is a resource-generation program that is tasked with: 1) identifying, collecting and intensively characterizing primary pancreatic tissues from patients with T2D and related forms of islet dysfunctions, as well as age-matched controls; and 2) curating, organizing, analyzing and sharing the data resulting from the study of these tissues through the PANC DB open-access resource database. HPAP-T2D is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.

Application due date: February 28, 2024 
Expiration date: February 29, 2024

Human Islet Research Network – Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed) (RFA-DK-23-004)

National Institute of Diabetes and Digestive and Kidney Diseases

This Notice of Funding Opportunity (NOFO) welcomes applications for the Consortium on Modeling Autoimmune Diabetes (CMAD) that supports the development of in vitro and in vivo models of type 1 diabetes (T1D) to enable studies of human T1D pathophysiology and to serve as platforms for preclinical assessments of new T1D interventions. CMAD is part of the Human Islet Research Network (HIRN).

Application due date: March 20, 2024
Earliest grant start date: December 2024



us on our social networks.